Journal: Cancer gene therapy

Article Title: In vitro and in vivo delivery of novel anticancer fusion protein MULT1E/FasTI via adenoviral vectors.

doi: 10.1038/cgt.2009.69

Figure Lengend Snippet: Figure 1 RT-PCR and FACS analyses. TC-1 cells were infected with Ad-MULT1E/FasTI at different MOIs. (a) RNAs were isolated from the infected cells and RT-PCR was performed. Lanes 1 and 14 are DNA markers; lines 2, 4, 6, 8, 10 and 12 are 1134bp RT-PCR products of total RNA from TC1 cells infected with Ad-MULT1E/FasTI at 500, 250, 100, 50, 25 or 0 MOIs and amplified with MULT1E forward and Fas reverse primers; lines 3, 5, 7, 9, 11 and 13 are b-actin controls for each sample. (b) 5 105 TC1 cells were harvested from each group that were infected with Ad-MULT1E/FasTI at 500, 250, 100, 50, 25 or 0 MOIs for 24 h and stained with purified rat anti-mouse MULT1 antibody followed by goat anti-mouse IgG F(ab0)-FITC. Dashed lines represent uninfected TC-1 cells.

Article Snippet: TC-1 cells infected with different MOIs of Ad-MULT1E/ FasTI (500, 250, 100, 50, 25 and 0) for 24 h were harvested and 5 105 cells from each sample were washed twice with staining buffer and incubated with 1 mg monoclonal rat anti-mouse MULT1 antibody (R&D Systems, Minneapolis, MN) for 30min at 4 1C.

Techniques: Reverse Transcription Polymerase Chain Reaction, Infection, Isolation, Amplification, Staining, Purification